87 related articles for article (PubMed ID: 3283688)
1. [Phenotypes of resistance to antibiotics of Acinetobacter baumannii. Impact on therapeutic orientation].
Ygout JF; Pasteau C; Mugnier P; Berlioux J; Daguet GL
Pathol Biol (Paris); 1988 Mar; 36(3):245-9. PubMed ID: 3283688
[TBL] [Abstract][Full Text] [Related]
2. Acinetobacter baumannii at a tertiary-care teaching hospital in Jerusalem, Israel.
Simhon A; Rahav G; Shazberg G; Block C; Bercovier H; Shapiro M
J Clin Microbiol; 2001 Jan; 39(1):389-91. PubMed ID: 11136809
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.
Dueñas Díez AI; Bratos Pérez MA; Eiros Bouza JM; Almaraz Gómez A; Gutiérrez Rodríguez P; Miguel Gómez MA; Orduña Domingo A; Rodríguez-Torres A
Int J Antimicrob Agents; 2004 May; 23(5):487-93. PubMed ID: 15120728
[TBL] [Abstract][Full Text] [Related]
4. [Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex].
Villar HE; Laurino G; Hoffman M
Enferm Infecc Microbiol Clin; 1996 Nov; 14(9):524-7. PubMed ID: 9035707
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.
Ishag AJ; Durgham SM; Shibl AM
Chemioterapia; 1987 Aug; 6(4):261-3. PubMed ID: 3477333
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method.
Quentin C; Saivin S; Lafferriere C; Noury P; Bebear C
Drugs Exp Clin Res; 1987; 13(4):219-24. PubMed ID: 3476291
[TBL] [Abstract][Full Text] [Related]
7. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of Acinetobacter strains identified by DNA-DNA hybridization.
Tjernberg I
APMIS; 1990 Apr; 98(4):320-6. PubMed ID: 2354051
[TBL] [Abstract][Full Text] [Related]
9. Characterization and changing minimum inhibitory concentration (MIC) of Acinetobacter species from a tertiary care setup.
Capoor MR; Nair D; Srivastava L; Gupta B; Aggarwal P
J Commun Dis; 2005 Jun; 37(2):99-107. PubMed ID: 16749272
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of antimicrobial agents against Acinetobacter calcoaceticus.
Joly-Guillou ML; Bergogne-Berezin E
Drugs Exp Clin Res; 1986; 12(12):949-52. PubMed ID: 3471431
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of antimicrobial susceptibility of Acinetobacter baumannii clinical isolates].
López-Hernández S; Alarcón T; López-Brea M
Rev Esp Quimioter; 2000 Dec; 13(4):394-400. PubMed ID: 11498706
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
[TBL] [Abstract][Full Text] [Related]
13. [In vitro action of fosfomycin combined with rifampicin, pefloxacin and imipenem on staphylococci (checkerboard method in a liquid medium)].
Quentin C; Noury P; Laurent C; Saivin S; Bebear C
Pathol Biol (Paris); 1987 Feb; 35(2):153-7. PubMed ID: 3550623
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of imipenem on Acinetobacter baumannii.
Hostacká A
Pharmazie; 1999 Jan; 54(1):70-2. PubMed ID: 9987801
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
[TBL] [Abstract][Full Text] [Related]
18. N-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics.
Martino P; Venditti M; Valente B; Brandimarte C; Serra P
Drugs Exp Clin Res; 1985; 11(4):247-51. PubMed ID: 3939121
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotic resistance of Acinetobacter baumannii isolates: data from Ibni Sina Hospital for the year 2002].
Akan OA
Mikrobiyol Bul; 2003 Oct; 37(4):241-6. PubMed ID: 14748260
[TBL] [Abstract][Full Text] [Related]
20. [Sensitivity to blood bactericidal activity and hydrophobicity of Acinetobacter baumannii after treatment with imipenem].
Hostacká A
Epidemiol Mikrobiol Imunol; 1999 Apr; 48(2):67-70. PubMed ID: 10349782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
